Treatment of central precocious puberty

Expert Opinion on Investigational Drugs

Volumn 15, Issue 5, 2006, Pages 495-505

  Tuvemo, Torsten ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

Author keywords

Buserelin; Central precocious puberty; Goserelin; Histrelin; Leuprolide; Naferelin; Triptorelin

Indexed keywords

ABARELIX; BUSERELIN; CETRORELIX; CYPROTERONE ACETATE; ESTRADIOL; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GOSERELIN; GROWTH HORMONE; HISTRELIN; LEUPRORELIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE; NAFARELIN; TEVERELIX; TRIPTORELIN;

ADRENAL DISEASE; BEHAVIOR; BODY HEIGHT; BONE DENSITY; BONE GROWTH; BONE MATURATION; BONE MINERAL; BONE STRENGTH; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; EOSINOPHILIA; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MENSTRUATION; NONHUMAN; OVARY POLYCYSTIC DISEASE; PAIN; PATHOGENESIS; PATIENT COMPLIANCE; PRECOCIOUS PUBERTY; REVIEW; SEX DIFFERENCE; SKIN ABSCESS; SKIN INDURATION; SOCIAL PSYCHOLOGY; TREATMENT FAILURE;

GONADOTROPIN-RELEASING HORMONE; HUMANS; PUBERTY, PRECOCIOUS; TREATMENT OUTCOME;

EID: 33646446922     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.5.495     Document Type: Review

References (93)

1. LEE PA: Normal ages of pubertal events among American males and females. J. Adolesc. Health Care (1980) 1(1):26-29.
2. HERMAN-GIDDENS ME, SLORA EJ, WASSERMAN RC et al.: Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics (1997) 99(4):505-512.
3. RITZEN EM: Early puberty: what is normal and when is treatment indicated? Horm. Res. (2003) 60(Suppl. 3):31-34.
4. TEILMANN G, PEDERSEN CB, JENSEN TK, SKAKKEBAEK NE, JUUL A: Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics (2005) 116(6):1323-1328.
5. DAHL M, PROOS LA, AHLSTEN G, TUVEMO T, GUSTAFSSON J: Increased intracranial pressure perinatally predicts early puberty in girls with myelomeningocele. Eur. J. Pediatr. Surg. (1996) 6(Suppl. 1):41-42.
6. PROOS LA, HOFVANDER Y, TUVEMO T: Menarcheal age and growth pattern of Indian girls adopted in Sweden. II. Catch-up growth and final height. Indian J. Pediatr. (1991) 58(1):105-114.
7. MASON P, NARAD C: International adoption: a health and developmental prospective. Semin. Speech Lang. (2005) 26(1):1-9.
8. ROGER M, CHAUSSAIN JL, BERLIER P et al.: Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J. Clin. Endocrinol. Metab. (1986) 62(4):670-677.
9. KAPLAN SA, LING SM, IRANI NG: Idiopathic isosexual precocity. Am. J. Dis. Child. (1968) 116(6):591-598.
10. BOURGUIGNON JP, VAN VLIET G, VANDEWEGHE M et al.: Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin). Eur. J. Pediatr. (1987) 146(6):555-560.
11. DROP SL, ODINK RJ, ROUWE C et al.: The effect of treatment with an LH-RH agonist (Buserelin) on gonadal activity growth and bone maturation in children with central precocious puberty. Eur. J. Pediatr. (1987) 146(3):272-278.
12. ANTONIAZZI F, ZAMBONI G: Central precocious puberty: current treatment options. Paediatr. Drugs (2004) 6(4):211-231.
13. HEGER S, SIPPELL WG, PARTSCH CJ: Gonadotropin-releasing hormone analogue treatment for precocious puberty. Twenty years of experience. Endocr. Dev. (2005) 8:94-125.
14. KNOBIL E, PLANT TM, WILDT L, BELCHETZ PE, MARSHALL G: Control of the rhesus monkey menstrual cycle: permissive role of hypothalamic gonadotropin-releasing hormone. Science (1980) 207(4437):1371-1373.
15. KNOBIL E: The neuroendocrine control of the menstrual cycle. Recent Prog. Horm. Res. (1980) 36:53-88.
16. TUVEMO T, JONSSON B, GUSTAFSSON J et al.: Final height after combined growth hormone and GnRH analogue treatment in adopted girls with early puberty. Acta Paediatr. (2004) 93(11):1456-1462.
17. CAREL JC, LAHLOU N, GUAZZAROTTI L et al.: Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur. J. Endocrinol. (1995) 132(6):699-704.
18. HISTRELIN Hydrogel Implant-Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. Drugs RD (2005) 6(1):53-55.
19. BOUCHARD P: [GnRH antagonists: present and future]. Ann. Urol. (Paris) (2005) 39(Suppl. 3):S56-S58.
20. BROQUA P, RIVIERE PJ, CONN PM, RIVIER JE, AUBERT ML, JUNIEN JL: Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J. Pharmacol. Exp. Ther. (2002) 301(1):95-102.
21. CHILLIK C, ACOSTA A: The role of LHRH agonists and antagonists. Reprod. Biomed. Online (2001) 2(2):120-128.
22. GILLIES PS, FAULDS D, BALFOUR JA, PERRY CM: Ganirelix. Drugs (2000) 59(1):107-111 (Discussion 112-113).
23. ROTH CL, NEU C, JARRY H, SCHOENAU E: Different effects of agonistic versus antagonistic gnrh-analogues (triptorelin versus cetrorelix) on bone modeling and remodeling in peripubertal female rats. Exp. Clin. Endocrinol. Diabetes (2005) 113(8):451-456.
24. ROTH CL, BRENDEL L, RUCKERT C, HARTMANN K: Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine. Horm. Res. (2005) 63(5):257-262.
25. SCHULTZE-MOSGAU A, GRIESINGER G, ALTGASSEN C, VON OTTE S, HORNUNG D, DIEDRICH K: New developments in the use of peptide gonadotropin-releasing hormone antagonists versus agonists. Expert Opin. Investig. Drugs (2005) 14(9):1085-1097.
26. WU MH, LIN SJ, WU LH, CHENG YC, CHOU YY, PAN HA: Clinical suppression of precocious puberty with cetrorelix after failed treatment with GnRH agonist in a girl with gonadotrophin-independent precocious puberty. Reprod. Biomed. Online (2005) 11(1):18-21.
27. XAVIER P, GAMBOA C, CALEJO L et al.: A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur. J. Obstet. Gynecol. Reprod. Biol. (2005) 120(2):185-189.
28. ARMER RE, SMELT KH: Non-peptidic GnRH receptor antagonists. Curr. Med. Chem. (2004) 11(22):3017-3028.
29. ANTONIAZZI F, CISTERNINO M, NIZZOLI G et al.: Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments. Acta Paediatr. (1994) 83(10):1052-1056.
30. CROWLEY WF Jr, COMITE F, VALE W, RIVIER J, LORIAUX DL, CUTLER GB Jr: Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty. J. Clin. Endocrinol. Metab. (1981) 52(2):370-372.
31. PAUL D, CONTE FA, GRUMBACH MM, KAPLAN SL: Long-term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J. Clin. Endocrinol. Metab. (1995) 80(2):546-551.
32. CACCIARI E, CASSIO A, BALSAMO A et al.: Long-term follow-up and final height in girls with central precocious puberty treated with luteinizing hormone-releasing hormone analogue nasal spray. Arch. Pediatr. Adolesc. Med. (1994) 148(11):1194-1199.
33. STANHOPE R, PRINGLE PJ, BROOK CG: Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin releasing hormone (GnRH) analogue. Acta Paediatr. Scand. (1988) 77(4):525-530.
34. STASIOWSKA B, VANNELLI S, BENSO L: Final height in sexually precocious girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (buserelin). Horm. Res. (1994) 42(3):81-85.
35. TUVEMO T: Expert report on the clinical documentation of GnRH analogues in the treatment of precocious puberty. Swedish Medical Products Agency, Uppsala, Sweden (1997).
36. BRAUNER R, ADAN L, MALANDRY F, ZANTLEIFER D: Adult height in girls with idiopathic true precocious puberty. J. Clin. Endocrinol. Metab. (1994) 79(2):415-420.
37. KAULI R, KORNREICH L, LARON Z: Pubertal development, growth and final height in girls with sexual precocity after therapy with the GnRH analogue D-TRP-6-LHRH. A report on 15 girls, followed after cessation of gonadotrophin suppressive therapy. Horm. Res (1990) 33(1):11-17.
38. MANASCO PK, PESCOVITZ OH, HILL SC et al.: Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty. J. Pediatr. (1989) 115(1):105-108.
39. SAGGESE G, BERTELLONI S, BARONCELLI GI, BATTINI R, FRANCHI G: Reduction of bone density: an effect of gonadotropin releasing hormone analogue treatment in central precocious puberty. Eur. J. Pediatr. (1993) 152(9):717-720.
40. SCHROOR EJ, VAN WEISSENBRUCH MM, DELEMARRE-VAN DE WAAL HA: Long-term GnRH-agonist treatment does not postpone central development of the GnRH pule generator in girls with idiopathic precocious puberty. J. Clin. Endocrinal. Metab. (1995) 80(5):1696-1701.
41. HEINRICHS C, CRAEN M, VANDERSCHUEREN-LODEWEYCKX M et al.: Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology. Acta Paediatr. (1994) 83(6):627-633.
42. JUUL A, SCHEIKE T, NIELSEN CT, KRABBE S, MULLER J, SKAKKEBAEK NE: Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate). J. Clin. Endocrinol. Metab. (1995) 80(10):3059-3067.
43. BOEPPLE PA, MANSFIELD MJ, CRAWFORD JD, CRIGLER JF Jr, BLIZZARD RM, CROWLEY WF Jr: Gonadotrophin-releasing hormone agonist treatment of central precocious puberty: an analysis of growth data in a developmental context. Acta Paediatr. Scand. Suppl. (1990) 367:38-43.
44. KREITER M, BURSTEIN S, ROSENFIELD RL et al.: Preserving adult height potential in girls with idiopathic true precocious puberty. J. Pediatr. (1990) 117(3):364-370.
45. STYNE DM: New aspects in the diagnosis and treatment of pubertal disorders. Pediatr. Clin. North Am. (1997) 44(2):505-529.
46. BRAUNER R, RAPPAPORT R: [Treatment of central precocious puberty with an LHRH analog. Effect on growth and bone maturation after 2 years of treatment]. Arch. Fr. Pediatr. (1987) 44(4):271-276.
47. NORJAVAARA E, ANKARBERG C, ALBERTSSON-WIKLAND K: Diurnal rhythm of 17 β-estradiol secretion throughout pubertal development in healthy girls: evaluation by a sensitive radioimmunoassay.J. Clin. Endocrinol. Metab. (1996) 81(11):4095-4102.
48. CAVALLO A, RICHARDS GE, BUSEY S, MICHAELS SE: A simplified gonadotrophin-releasing hormone test for precocious puberty. Clin. Endocrinol. (Oxf.) (1995) 42(6):641-646.
49. NEELY EK, WILSON DM, LEE PA, STENE M, HINTZ RL: Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J. Pediatr. (1995) 127(1):47-52.
50. BOURGUIGNON JP, HEINRICHS C, VAN VLIET G et al.: Evaluation and significance of the degree of pituitary-gonadal inhibition during intranasal administration of buserelin. Acta Endocrinol. (Copenh.) (1987) 116(4):519-525.
51. CAREL JC, LAHLOU N, JARAMILLO O et al.: Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J. Clin. Endocrinol. Metab. (2002) 87(9):4111-4116.
52. MOURIDSEN SE, LARSEN FW: Psychological aspects of precocious puberty. An overview. Acta Paedopsychiatr. (1992) 55(1):45-49.
53. EHRHARDT AA, MEYER-BAHLBURG HF: Psychosocial aspects of precocious puberty. Horm. Res. (1994) 41(Suppl. 2):30-35.
54. WILLIAMS JK: Parenting a daughter with precocious puberty or Turner syndrome. J. Pediatr. Health Care (1995) 9(3):109-114.
55. APTER A, GALATZER A, WEIZMAN A, WEIZMAN T, MODAI I, LARON Z: Psychological aspects of developmental endocrinopathies in adolescence. Isr, J. Pychiatry Relat. Sci. (1994) 31(4):246-253.
56. MUL D, OOSTDIJK W, WAELKENS JJ, SCHULPEN TW, DROP SL: Gonadotrophin releasing hormone agonist treatment with or without recombinant human GH in adopted children with early puberty. Clin. Endocrinol. (Oxf.) (2001) 55(1):121-129.
57. JOHANSSON T: Very long term follow-up of girls with early and late menarche. In: Abnormalities in puberty, Delemarre van de Waal H (Ed.), Karger (2006):126-136.
58. KLETTER GB, KELCH RP: Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J. Clin. Endocrinol. Metab. (1994) 79(2):331-334.
59. OERTER KE, MANASCO PK, BARNES KM, JONES J, HILL S, CUTLER GB Jr: Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty. Acta Paediatr. Suppl. (1993) 388:62-68 (Discussion 69).
60. OOSTDIJK W, RIKKEN B, SCHREUDER S et al.: Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch. Dis. Child. (1996) 75(4):292-297.
61. THAMDRUP E: Precocious sexual development: a clinical study of one hundred children. Dan. Med. Bull. (1961) 8:140-142.
62. KAULI R, GALATZER A, KORNREICH L, LAZAR L, PERTZELAN A, LARON Z: Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm. Res. (1997) 47(2):54-61.
63. BAR A, LINDER B, SOBEL EH, SAENGER P, DI MARTINO-NARDI J: Bayley-Pinneau method of height prediction in girls with central precocious puberty: correlation with adult height. J. Pediatr. (1995) 126(6):955-958.
64. HOLLAND FJ, FISHMAN L, COSTIGAN DC, LUNA L, LEEDER S: Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10 luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin. Endocrinol. Metab. (1986) 63(5):1065-1070.
65. LANES R, SOROS A, JAKUBOWICZ S: Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs. J Pediatr. Endocrinol. Metab. (2004) 17(5):759-766.
66. KLEIN KO, BARNES KM, JONES JV, FEUILLAN PP, CUTLER GB Jr: Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J. Clin. Endocrinol, Metab. (2001) 86(10):4711-4716.
67. KAPLOWITZ PB, OBERFIELD, SE: Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics (1999) 104(4 Part 1):936-941.
68. PARTSCH CJ, HUMMELINK R, PETER M et al.: Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group. Horm. Res. (1993) 39(3-4):111-117.
69. MUL D, OOSTDIJK W, WAELKENS JJ, DROP SL: Final height after treatment of early puberty in short adopted girls with gonadotrophin releasing hormone agonist with or without growth hormone. Clin. Endocrinol. (Oxf.) (2005) 63(2):185-190.
70. PUCARELLI I, SEGNI M, ORTORE M, MORETTI A, IANNACCONE R, PASQUINO AM: Combined therapy with GnRH analog plus growth hormone in central precocious puberty. J. Pediatr. Endocrinol. Metab. (2000) 13(Suppl. 1):811-820.
71. PUCARELLI I, SEGNI M, ORTORE M, ARCADI E, PASQUINO AM: Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J. Pediatr. Endocrinol. Metab. (2003) 16(7):1005-1010.
72. TATO L, SAGGESE G, CAVALLO L et al.: Use of combined Gn-RH agonist and hGH therapy for better attining the goals in precocious puberty treatment. Horm. Res. (1995) 44(Suppl. 3):49-54.
73. SAGGESE G, PASQUINO AM, BERTELLONI S et al.: Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. Acta Paediatr. (1995) 84(3):299-304.
74. PROOS LH, LONNERHOLM T, JONSSON B, TUVEMO T: Can bone age determination provide criteria for growth hormone treatment in adopted girls with early puberty? Upsala J. Med. Sci. (2006) 111(1):117-129.
75. ROGER M, CHAUSSAIN JL, BOST M et al.: [Treatment of precocious puberty with LH-RH agonists. Multicenter study using D-Trp-6-LH-RH in a programmed-release form]. Rev. Fr. Gynecol. Obstet. (1986) 81(5):297-305.
76. NEELY EK, HINTZ RL, PARKER B et al.: Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J. Pediatr. (1992) 121(4):634-640.
77. MANASCO PK, PESCOVITZ OH, BLIZZARD RM: Local reactions to depot leuprolide therapy for central precocious puberty. J. Pediatr. (1993) 123(2):334-335.
78. TONINI G, MARINONI S, FORLEO V, RUSTICO M: Local reactions to luteinizing hormone releasing hormone analog therapy. J. Pediatr. (1995) 126(1):159-160.
79. KAUSCHANSKY A, NUSSINOVITCH M, FRYDMAN M, YESHAYA A, BEN-RAFAEL Z: Hyperprolactinemia after treatment of long-acting gonadotropin-releasing hormone analogue Decapeptyl in girls with central precocious puberty. Fertil. Steril. (1995) 64(2):285-287.
80. SKLAR CA, ROTHENBERG S, BLUMBERG D, OBERFIELD SE, LEVINE LS, DAVID R: Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion. J. Clin. Endocrinol. Metab. (1991) 73(4):734-738.
81. VERROTTI A, CHIARELLI F, MONTANARO AF, MORGESE G: Bone mineral content in girls with precocious puberty treated with gonadotropin-releasing hormone analog. Gynecol. Endocrinol. (1995) 9(4):277-281.
82. MANASCO PK, PESCOVITZ OH, FEUILLAN PP et al.: Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J. Clin. Endocrinol. Metab. (1988) 67(2):368-372.
83. TANAKA T, NIIMI H, MATSUO N et al.: Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J. Clin. Endocrinol. Metab. (2005) 90(3):1371-1376.
84. TONINI G, LAZZERINI M: Side effects of GnRH analogue treatment in childhood. J. Pediatr. Endocrinol. Metab. (2000) 13(Suppl. 1):795-803.
85. BRIDGES NA, COOKE A, HEALY MJ, HINDMARSH PC, BROOK CG: Ovaries in sexual precocity. Clin. Endocrinol. (Oxf.) (1995) 42(2):135-140.
86. ROOT AW, MOSHANG T Jr: Evolution of the hyperandrogenism-polycystic ovary syndrome from isosexual precocious puberty: report of two cases. Am. J. Obstet. Gynecol. (1984) 149(7):763-767.
87. NEELY EK, BACHRACH LK, HINTZ RL et al.: Bone mineral density during treatment of central precocious puberty. J. Pediatr. (1995) 127(5):819-822.
88. UNAL O, BERBEROGLU M, EVLIYAOGLU O, ADIYAMAN P, AYCAN Z, OCAL G: Effects on bone mineral density of gonadotropin releasing hormone analogs used in the treatment of central precocious puberty. J. Pediatr. Endocrinol. Metab. (2003) 16(3):407-411.
89. ANTONIAZZI F, BERTOLDO F, ZAMBONI G et al.: Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur. J. Endocrinol. (1995) 133(4):412-417.
90. ANTONIAZZI F, ZAMBONI G, BERTOLDO F et al.: Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J. Clin. Endocrinol. Metab. (2003) 88(3):1096-1101.
91. MUL D, BERTELLONI S, CAREL JC, SAGGESE G, CHAUSSAIN JL, OOSTDIJK W: Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: final height results. Horm. Res. (2002) 58(1):1-7.
92. CAREL JC, LAHLOU N, ROGER M, CHAUSSAIN JL: Precocious puberty and statural growth. Hum. Reprod. Update (2004) 10(2):135-147.
93. CAREL JC: Can we increase adolescent growth? Eur. J. Endocrinol. (2004) 151(Suppl. 3):U101-U108.